Acadian Asset Management LLC Adverum Biotechnologies, Inc. Transaction History

Acadian Asset Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.75 - $1.26 $20,951 - $35,198	27,935 New	27,935 $20,000
Q4 2022 Feb 14, 2023	BUY	$0.54 - $10.3 $69,774 - $1.33 Million	129,212 New	129,212 $74,000
Q3 2021 Nov 12, 2021	SELL	$2.08 - $3.6 $85,904 - $148,680	-41,300 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$3.36 - $10.56 $138,768 - $436,128	41,300 New	41,300 $144,000
Q4 2019 Feb 06, 2020	SELL	$5.12 - $12.22 $81,694 - $194,982	-15,956 Closed	0 $0
Q3 2019 Nov 07, 2019	SELL	$5.24 - $15.89 $48,139 - $145,981	-9,187 Reduced 36.54%	15,956 $87,000
Q2 2019 Aug 08, 2019	BUY	$5.1 - $11.89 $76,607 - $178,599	15,021 Added 148.4%	25,143 $299,000
Q1 2019 May 09, 2019	BUY	$3.03 - $6.02 $30,669 - $60,934	10,122 New	10,122 $53,000
Q2 2018 Jul 24, 2018	SELL	$5.3 - $6.9 $268,195 - $349,160	-50,603 Closed	0 $0
Q1 2018 Apr 12, 2018	BUY	$3.65 - $7.95 $184,700 - $402,293	50,603 New	50,603 $293,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.